Access the full text.
Sign up today, get DeepDyve free for 14 days.
H. Towbin, T. Staehelin, J. Gordon (1979)
Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.Proceedings of the National Academy of Sciences of the United States of America, 76 9
S. Kajigaya, M. Momoeda (1997)
Immune Response to B19 Infection, 20
Maria Soderlund, Kevin Brown, Olli Meurman, '. Klaushedman (1992)
Prokaryotic expression of a VP1 polypeptide antigen for diagnosis by a human parvovirus B19 antibody enzyme immunoassayJournal of Clinical Microbiology, 30
G. Kurtzman, B. Cohen, A. Field, R. Oseas, R. Blaese, N. Young (1989)
Immune response to B19 parvovirus and an antibody defect in persistent viral infection.The Journal of clinical investigation, 84 4
L. Larsson (1976)
HUMAN PANCREATIC POLYPEPTIDE, VASOACTIVE INTESTINAL POLYPEPTIDE, AND WATERY DIARRHŒA SYNDROMEThe Lancet, 308
K. Brown, N. Young, J. Liu (1994)
Molecular, cellular and clinical aspects of parvovirus B19 infection.Critical reviews in oncology/hematology, 16 1
M. Zerbini, M. Musiani, S. Venturoli, G. Gallinella, D. Gibellini, G. Gentilomi, M. Placa (1990)
Rapid screening for B19 parvovirus DNA in clinical specimens with a digoxigenin-labeled DNA hybridization probeJournal of Clinical Microbiology, 28
C. Brown, M. Salimans, M. Noteborn, H. Weiland (1990)
Antigenic parvovims B19 coat proteins VP1 and VP2 produced in large quantities in a baculovirus expression systemVirus Research, 15
P. Palmer, C. Pallier, M. Leruez-Ville, M. Deplanche, F. Morinet (1996)
Antibody response to human parvovirus B19 in patients with primary infection by immunoblot assay with recombinant proteinsClinical Diagnostic Laboratory Immunology, 3
M. Söderlund, C. Brown, Willy Spaan, L. Hedman, Klaus Hedman (1995)
Epitope type-specific IgG responses to capsid proteins VP1 and VP2 of human parvovirus B19.The Journal of infectious diseases, 172 6
T. Schwarz, Michael Roggendorf, F. Deinhardt (1988)
Human parvovirus B19: ELISA and immunoblot assays.Journal of virological methods, 20 2
G. Gallinella, M. Musiani, M. Zerbini, G. Gentilomi, D. Gibellini, S. Venturoli, M. Placa (1993)
Efficient parvovirus B19 DNA purification and molecular cloning.Journal of virological methods, 41 2
Anderson Anderson (1990)
Human parvovirusesJ Inf Dis, 161
Pattison Pattison (1994)
Human parvovirus B19Lancet, 308
M. Zerbini, M. Musiani, G. Gentilomi, S. Venturoli, G. Gallinella, R. Morandi (1996)
Comparative evaluation of virological and serological methods in prenatal diagnosis of parvovirus B19 fetal hydropsJournal of Clinical Microbiology, 34
S. Kajigaya, H. Fujii, A. Field, S. Anderson, S. Rosenfeld, L. Anderson, T. Shimada, N. Young (1991)
Self-assembled B19 parvovirus capsids, produced in a baculovirus system, are antigenically and immunogenically similar to native virions.Proceedings of the National Academy of Sciences of the United States of America, 88 11
M. Musiani, A. Azzi, M. Zerbini, D. Gibellini, S. Venturoli, K. Zakrzewska, M. Re, G. Gentilomi, G. Gallinella, M. Placa (1993)
Nested polymerase chain reaction assay for the detection of B19 parvovirus DNA in human immunodeficiency virus patientsJournal of Medical Virology, 40
F. Morinet, L. d'Auriol, J. Tratschin, F. Galibert (1989)
Expression of the human parvovirus B19 protein fused to protein A in Escherichia coli: recognition by IgM and IgG antibodies in human sera.The Journal of general virology, 70 ( Pt 11)
Human B19 parvovirus recombinant capsid proteins VP1 and VP2 were expressed in E. coli and purified. Recombinant proteins were used to detect a specific IgG immune response against VP1 and VP2 linear epitopes by immunoblot assay. A total of 222 serum samples from 218 apparently immunocompetent subjects with different clinical conditions and laboratory evaluations with regards to B19 infection were analyzed. The sera had previously been tested for B19 DNA and for specific IgM and IgG against VP2 conformational antigens by ELISA assay. The data show that, during the active or very recent phase of infection, IgG anti‐VP1 linear epitopes appear in concomitance and with the same frequency as IgG anti‐VP2 conformational antigens. IgG against conformational VP2 antigens and against linear VP1 epitopes seem to persist for months or years in the majority of individuals. IgG against VP2 linear epitopes are generally present during the active or very recent phase of infection and during the convalescent phase, while they are present only in about 20% of subjects with signs of a past B19 infection. J. Med. Virol. 57:174–178, 1999. © 1999 Wiley‐Liss, Inc.
Journal of Medical Virology – Wiley
Published: Feb 1, 1999
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.